We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
S100A16 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
325.5
Number of samples
141
Samples
Sample
Description
TPM
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
1098.6
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
752.6
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
749.0
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
714.4
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
713.1
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
680.3
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
672.3
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
668.0
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
653.7
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
627.7
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
620.3
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
601.5
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
597.6
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
583.8
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
536.2
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
534.8
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
532.8
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
525.9
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
502.5
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
500.0
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
490.7
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
487.6
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
485.6
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
480.0
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
477.6
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
474.3
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
472.5
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
462.6
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
460.7
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
457.4
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
455.3
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
446.3
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
436.6
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
426.6
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
423.8
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
421.4
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
415.7
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
410.1
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
406.8
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
404.6
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
404.3
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
399.2
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
398.7
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
396.7
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
395.3
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
394.5
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
393.6
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
389.1
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
388.2
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
385.4
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
370.0
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
361.9
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
353.0
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
352.1
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
351.3
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
350.0
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
344.8
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
339.5
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
338.8
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
338.2
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
336.1
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
334.5
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
330.7
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
328.0
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
327.8
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
324.0
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
321.2
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
317.1
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
316.7
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
311.6
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
311.3
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
305.5
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
299.6
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
298.3
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
297.6
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
295.8
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
293.5
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
291.4
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
291.0
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
288.9
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
281.0
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
271.4
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
269.6
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
267.5
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
263.5
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
262.8
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
261.8
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
261.5
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
259.0
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
257.2
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
255.2
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
252.4
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
249.9
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
248.2
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
236.5
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
236.0
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
234.9
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
230.4
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
227.0
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
225.7
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
222.8
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
217.5
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
208.7
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
208.2
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
207.2
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
206.6
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
205.6
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
196.1
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
194.2
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
193.1
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
183.4
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
172.7
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
168.5
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
165.1
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
164.4
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
156.3
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
154.7
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
149.1
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
143.7
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
140.7
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
139.0
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
137.7
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
134.0
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
128.6
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
121.2
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
114.9
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
111.7
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
90.6
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
75.1
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
73.9
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
71.7
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
67.1
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
66.6
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
52.1
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
51.8
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
49.4
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
41.5
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
38.7
TCGA-26-5134-01A
74 years, male, white, stage:'--, alive, 167 days
36.2
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
S100A16 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
35.4
Number of samples
58
Samples
Sample
Description
TPM
AK236
N, NA, stage:NA, dead, 360 days
94.8
AK227
N, NA, stage:NA, alive, 300 days
88.8
AK183
N, NA, stage:NA, alive, 360 days
81.9
AK055
N, NA, stage:NA, dead, 240 days
78.7
AK088
N, NA, stage:NA, dead, 360 days
78.7
AK153
N, NA, stage:NA, dead, 240 days
67.3
AK123
N, NA, stage:NA, dead, 180 days
65.2
AK178
N, NA, stage:NA, dead, 240 days
65.0
AK099
N, NA, stage:NA, dead, 420 days
59.9
AK071
N, NA, stage:NA, dead, 540 days
56.7
AK195
N, NA, stage:NA, dead, 390 days
56.2
AK068
N, NA, stage:NA, alive, 360 days
55.5
AK185
N, NA, stage:NA, alive, 330 days
55.0
AK006
N, NA, stage:NA, dead, 360 days
53.1
AK100
N, NA, stage:NA, alive, 960 days
52.2
AK072
N, NA, stage:NA, dead, 150 days
47.5
AK076
N, NA, stage:NA, alive, 660 days
43.5
AK139
N, NA, stage:NA, dead, 270 days
42.6
AK091
N, NA, stage:NA, dead, 210 days
41.5
AK134
N, NA, stage:NA, dead, 360 days
39.5
AK226
N, NA, stage:NA, dead, 360 days
38.6
AK133
N, NA, stage:NA, dead, 360 days
38.3
AK074
N, NA, stage:NA, alive, 300 days
37.2
AK158
N, NA, stage:NA, dead, 360 days
36.7
AK188
N, NA, stage:NA, alive, 420 days
36.6
AK216
N, NA, stage:NA, dead, 360 days
36.6
AK089
N, NA, stage:NA, dead, 330 days
35.3
AK205
N, NA, stage:NA, dead, 120 days
34.8
AK049
N, NA, stage:NA, dead, 180 days
33.2
AK231
N, NA, stage:NA, dead, 240 days
31.5
AK053
N, NA, stage:NA, dead, 300 days
29.0
AK218
N, NA, stage:NA, dead, 180 days
27.8
AK051
N, NA, stage:NA, dead, 360 days
27.3
AK030
N, NA, stage:NA, dead, 120 days
27.1
AK085
N, NA, stage:NA, alive, 660 days
26.3
AK117
N, NA, stage:NA, dead, 210 days
25.6
AK041
N, NA, stage:NA, alive, 810 days
25.4
AK098
N, NA, stage:NA, dead, 660 days
24.1
AK199
N, NA, stage:NA, alive, 1860 days
23.8
AK035
N, NA, stage:NA, dead, 210 days
23.5
AK149
N, NA, stage:NA, dead, 420 days
22.4
AK165
N, NA, stage:NA, alive, 360 days
20.0
AK003
N, NA, stage:NA, dead, 600 days
19.4
AK142
N, NA, stage:NA, alive, 90 days
18.8
AK156
N, NA, stage:NA, dead, 330 days
15.6
AK005
N, NA, stage:NA, dead, 240 days
15.6
AK015
N, NA, stage:NA, alive, 720 days
15.3
AK103
N, NA, stage:NA, alive, 1320 days
12.6
AK079
N, NA, stage:NA, dead, 210 days
12.5
AK173
N, NA, stage:NA, dead, 180 days
12.1
AK167
N, NA, stage:NA, dead, 180 days
8.9
AK102
N, NA, stage:NA, alive, 1740 days
8.3
AK081
N, NA, stage:NA, dead, 180 days
7.6
AK124
N, NA, stage:NA, alive, 1920 days
7.1
AK066
N, NA, stage:NA, alive, 960 days
5.5
AK043
N, NA, stage:NA, alive, 660 days
5.1
AK213
N, NA, stage:NA, alive, 2010 days
4.2
AK002
N, NA, stage:NA, dead, 570 days
3.9
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0087950003
Tumor
1.1
CPT0221180003
Tumor
1.1
CPT0206230003
Tumor
1.0
CPT0190360004
Tumor
1.0
CPT0125570003
Tumor
0.9
CPT0089150003
Tumor
0.9
CPT0225730003
Tumor
0.8
CPT0093590003
Tumor
0.7
CPT0205450004
Tumor
0.7
CPT0093360003
Tumor
0.6
CPT0225760003
Tumor
0.6
CPT0168830003
Tumor
0.6
CPT0167750004
Tumor
0.6
CPT0162140003
Tumor
0.6
CPT0093550003
Tumor
0.6
CPT0216920008
Tumor
0.6
CPT0217000004
Tumor
0.6
CPT0168080003
Tumor
0.5
CPT0218690004
Tumor
0.5
CPT0162100003
Tumor
0.5
CPT0189750004
Tumor
0.5
CPT0206000004
Tumor
0.5
CPT0224330003
Tumor
0.5
CPT0079790003
Tumor
0.5
CPT0218830004
Tumor
0.4
CPT0189650004
Tumor
0.4
CPT0206560003
Tumor
0.4
CPT0207030003
Tumor
0.4
CPT0168590003
Tumor
0.3
CPT0206330003
Tumor
0.3
CPT0104220003
Tumor
0.3
CPT0201710003
Tumor
0.3
CPT0092440003
Tumor
0.3
CPT0224390004
Tumor
0.3
CPT0182500003
Tumor
0.3
CPT0168270003
Tumor
0.3
CPT0217060003
Tumor
0.3
CPT0209440003
Tumor
0.2
CPT0002410011
Tumor
0.2
CPT0217710008
Tumor
0.2
CPT0217190003
Tumor
0.2
CPT0217100003
Tumor
0.2
CPT0219080004
Tumor
0.2
CPT0125220003
Tumor
0.2
CPT0206110003
Tumor
0.2
CPT0162020003
Tumor
0.2
CPT0218890004
Tumor
0.2
CPT0206780003
Tumor
0.2
CPT0078580003
Tumor
0.1
CPT0087570003
Tumor
0.1
CPT0168480003
Tumor
0.1
CPT0218960004
Tumor
0.1
CPT0167530003
Tumor
0.1
CPT0167640003
Tumor
0.1
CPT0206450003
Tumor
0.0
CPT0217430008
Tumor
0.0
CPT0064650003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0168720003
Tumor
0.0
CPT0167860004
Tumor
0.0
CPT0204330003
Normal
-0.1
CPT0224540004
Tumor
-0.1
CPT0206880003
Tumor
-0.1
CPT0167970003
Tumor
-0.1
CPT0093450003
Tumor
-0.1
CPT0205570003
Tumor
-0.1
CPT0087730003
Tumor
-0.1
CPT0204360003
Normal
-0.1
CPT0218330004
Tumor
-0.1
CPT0171580008
Tumor
-0.1
CPT0205780003
Tumor
-0.1
CPT0168380003
Tumor
-0.1
CPT0204350003
Normal
-0.2
CPT0175060003
Tumor
-0.2
CPT0196850003
Tumor
-0.2
CPT0205890003
Tumor
-0.2
CPT0199770003
Tumor
-0.2
CPT0127420003
Tumor
-0.2
CPT0204420003
Normal
-0.2
CPT0127480003
Tumor
-0.2
CPT0093510003
Tumor
-0.3
CPT0204390003
Normal
-0.3
CPT0064890003
Tumor
-0.3
CPT0217880003
Tumor
-0.3
CPT0206670004
Tumor
-0.3
CPT0104330003
Tumor
-0.3
CPT0204380003
Normal
-0.3
CPT0224600003
Tumor
-0.3
CPT0125510003
Tumor
-0.4
CPT0071100003
Tumor
-0.4
CPT0123530003
Tumor
-0.4
CPT0204410003
Normal
-0.4
CPT0205670004
Tumor
-0.4
CPT0208980003
Tumor
-0.5
CPT0182580003
Tumor
-0.5
CPT0204370003
Normal
-0.5
CPT0182550003
Tumor
-0.6
CPT0189250003
Tumor
-0.6
CPT0087680003
Tumor
-0.7
CPT0190240004
Tumor
-0.7
CPT0186100003
Tumor
-0.7
CPT0161730003
Tumor
-0.7
CPT0207090003
Tumor
-0.7
CPT0189570004
Tumor
-0.8
CPT0189850004
Tumor
-0.8
CPT0204400003
Normal
-0.9
CPT0204340003
Normal
-0.9
CPT0218770003
Tumor
-1.4
CPT0228220003
Tumor
-1.6
CPT0218670003
Tumor
-1.9
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.